Gan & Lee Pharmaceuticals.
Clinical trials sponsored by Gan & Lee Pharmaceuticals., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New insulin rival: can GZR4 beat current options for diabetes? Results expected Nov 2026 (estimated)
- New diabetes shot GZR18 takes on semaglutide in major trial Results expected Dec 2026 (estimated)
- New diabetes shot aims to help when pills or insulin fall short Results expected Feb 2027 (estimated)
- New Weight-Loss drug GZR18 takes on wegovy in major trial Results expected Jun 2027 (estimated)
- Could a pill help tackle obesity? new drug enters human testing Results expected Aug 2027 (estimated)
-
New insulin challenger: can GZR33 beat the standard for diabetes control?
Disease control Recruiting nowThis Phase 3 trial will test a new once-daily insulin, GZR33, against the standard insulin degludec (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by oral medications. The main goal is to see how well GZR33 lowers blood sugar over 26 weeks c…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Weight loss shot moves to monthly dosing in new trial
Disease control Recruiting nowThis Phase 3 study tests whether switching to a once-monthly injection of GZR18 can help 500 overweight or obese adults maintain weight loss for an additional 24 weeks. All participants previously completed a year of biweekly GZR18 treatment. The study measures changes in body we…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New obesity drug GZR18 under microscope: how does it interact with common meds?
Disease control Recruiting nowThis early-stage study tests GZR18, an injectable drug for obesity or overweight, in 60 Chinese adults. Researchers want to see how it affects stomach emptying and whether it changes how the body processes digoxin (heart medication), rosuvastatin (cholesterol drug), and warfarin …
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New insulin rival: can GZR4 beat current options for diabetes?
Disease control Recruiting nowThis study tests a new insulin drug, GZR4, against another insulin (Insulin Icodec) in 300 adults with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and causes fewer side effects like low blood sugar. Participants may also…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New Weight-Loss drug GZR18 takes on wegovy in major trial
Disease control Recruiting nowThis Phase 3 trial compares a new injectable drug, GZR18, to the popular weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. Researchers will also check for s…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Healthy men needed to check if updated obesity drug matches original
Knowledge-focused Recruiting nowThis study checks if a new version of the GZR18 injection works the same as the old version in healthy adult men. About 138 men will get a single shot and have their blood tested over 35 days. The goal is to see if the drug levels in the body are similar, not to treat any disease…
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New obesity drug tested in kidney patients: dosing clues sought
Knowledge-focused Recruiting nowThis early-stage study tests a single dose of the drug GZR18 in 32 adults who are overweight or obese, some with mild to severe kidney problems and some with normal kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to find the right …
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC